Abstract:OBJECTIVE:Tacrolimus is used clinically for the long-term treatment of antirejection of transplanted organs in liver and kidney transplant recipients, although dose optimization is poorly managed. The aim of this study was to examine the association between tacrolimus pharmacokinetic variability and CYP3A4 and CYP3A5 genotypes by a population pharmacokinetic analysis based on routine drug monitoring data in adult renal transplant recipients.MATERIALS AND METHODS:Trough tacrolimus concentrations were obtained from 161 adult kidney transplant recipients after transplantation. The population pharmacokinetic analysis was carried out using the nonlinear mixed-effect modeling software NONMEM version 7.2. The CYP3A4*1G and CYP3A5*3 genetic polymorphisms from the patients studied were determined by direct sequencing using a validated automated genetic analyzer.RESULTS:A one-compartment model with first-order absorption and elimination adequately described the pharmacokinetics of tacrolimus. Covariates including CYP3A5*3 and CYP3A4*1G alleles and hematocrit were retained in the final model. The apparent clearance of tacrolimus was about two-fold higher in kidney transplant patients with higher enzymatic activity of CYP3A5*1 and CYP3A4*1G (with the CYP3A5*1/*1 or *1/*3 and CYP3A4*1/*1G or CYP3A4*1G/*1G) compared with those with lower enzymatic activity (CYP3A5*3/*3 and CYP3A4*1/*1).CONCLUSION:This is the first study to extensively determine the effect of CYP3A4*1G and CYP3A5*3 genetic polymorphisms and hematocrit value on tacrolimus pharmacokinetics in Chinese renal transplant recipients. The findings suggest that CYP3A5*3 and CYP3A4*1G polymorphisms and hematocrit are determinant factors in the apparent clearance of tacrolimus. The initial dose design is mainly based on CYP3A5 and CYP3A4 genotypes as well as hematocrit. This result may also be useful for maintenance tacrolimus dose optimization and may help to avoid fluctuating tacrolimus levels and improve the efficacy and tolerability of tacrolimus in kidney transplant recipients.

FOXP3 Rs3761548 Polymorphism is Associated with Tacrolimus-Induced Acute Nephrotoxicity in Renal Transplant Patients

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

Influence of TLR4 Rs1927907 Locus Polymorphisms on Tacrolimus Pharmacokinetics in the Early Stage after Liver Transplantation

Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients.

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients

Association Between Interleukin-18 Promoter Variants and Tacrolimus Pharmacokinetics in Chinese Renal Transplant Patients

TLR10 Genotypes Affect Long-Term Graft Function in Tacrolimus-Treated Solid Organ Transplant Recipients.

Association of CYP3A5 and IL-10 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Lung Transplantation Recipients

Polymorphisms of Tumor Necrosis Factor-Α, Interleukin-10, Cytochrome P450 3A5 and ABCB1 in Chinese Liver Transplant Patients Treated with Immunosuppressant Tacrolimus

Effects of CYP3A4 and CYP3A5 Polymorphisms on Tacrolimus Pharmacokinetics in Chinese Adult Renal Transplant Recipients: a Population Pharmacokinetic Analysis.

Donor Il-18 Rs5744247 Polymorphism As A New Biomarker Of Tacrolimus Elimination In Chinese Liver Transplant Patients During The Early Post-Transplantation Period: Results From Two Cohort Studies

Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.

Impact of Interleukin-10 Gene Polymorphisms on Tacrolimus Dosing Requirements in Chinese Liver Transplant Patients During the Early Posttransplantation Period.

Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients

The Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients.

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients